@article {PULA4059, author = {BARTOSZ PULA and BOZENA WERYNSKA and MATEUSZ OLBROMSKI and BEATA MUSZCZYNSKA-BERNHARD and MARIUSZ CHABOWSKI and DARIUSZ JANCZAK and MACIEJ ZABEL and MARZENA PODHORSKA-OKOLOW and PIOTR DZIEGIEL}, title = {Expression of Nogo Isoforms and Nogo-B Receptor (NgBR) in Non-small Cell Lung Carcinomas}, volume = {34}, number = {8}, pages = {4059--4068}, year = {2014}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Nogo-B was recently shown to be involved in proliferation, apoptosis and invasiveness of cancer cells, whereas its specific receptor (NgBR) was found to be up-regulated in estrogen receptor-α positive breast cancer. No data are currently available concerning their expression in non-small cell lung carcinomas (NSCLC). Materials and Methods: Expression of Nogo isoforms and NgBR was studied in 191 NSCLC. Results: Higher Nogo-A/B immunoreactivity was noted in cancer cells of squamous cell carcinomas (SQC) compared to adenocarcinomas (p\<0.001). Stage II-IV tumors had the lowest Nogo-A/B expression (p\<0.0001) compared to stage I cases. Nogo-A/B expression decreased with increasing SQC malignancy grade (p=0.026). Significant NgBR mRNA down-regulation was associated with larger primary tumor size (p=0.039), lymph node involvement (p=0.039) and advancement stage (p=0.0054). Low NgBR mRNA expression predicted poor patients outcome (p=0.029). Conclusion: The current data may point to the involvement of Nogo isoforms and NgBR in the pathogenesis of NSCLC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/34/8/4059}, eprint = {https://ar.iiarjournals.org/content/34/8/4059.full.pdf}, journal = {Anticancer Research} }